News >

Therapeutic Breakthroughs in AML Lead to Improvements in OS Outcomes

Brandon Scalea
Published: Thursday, Mar 07, 2019

Dr. Naval Daver

Naval Daver, MD

A wealth of new drugs and novel combinations has significantly improved 5-year overall survival (OS) rates for elderly patients with acute myeloid leukemia (AML); however, the remaining challenge for research involves determining where these emerging strategies best fit in with traditional therapies, according to Naval G. Daver, MD.

Daver discussed the recent advances made in AML, stressed the importance of minimal residual disease (MRD) testing, and highlighted where research in the field is heading in order to achieve a higher cure rate.

OncLive®: What are the current treatment options for patients with AML?

Daver: There are now many treatment options for patients with AML. It has been a fantastic last 2 years, with 8 drugs approved and a couple of drugs also under FDA review. [These developments have] dramatically shifted the landscape of AML. Historically, we selected treatment based on the fitness and age of the patient. Therefore, if patients were considered fit enough to receive high-dose chemotherapy, they were given induction with the 7 + 3 regimen or the 7 + 3 “light” regimen. Those who were not considered fit enough because of their age or performance status were given low-intensity therapy. Although we were able to cure about 50% of younger patients, only about 15% to 20% of older patients were cured.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication